Kidney Week

Abstract: SA-PO810

Iron Supplementation for Hemodialysis Patients: Less Oxidative Stress by Oral Ferric Citrate Hydrate as Compared to Intravenous Saccharated Ferric Oxide

Session Information

• Dialysis: Anemia and Iron Metabolism
  November 04, 2017 | Location: Hall H, Morial Convention Center
  Abstract Time: 10:00 AM - 10:00 AM

Category: Dialysis

• 605 Dialysis: Anemia and Iron Metabolism

Authors

• Nakayama, Masaaki, Tohoku University, Tohoku University Hospital, Sendai City, Japan

Masaaki Nakayama,

• Tani, Yoshihiro, Fukushima Medical University, Fukushima, Japan

Yoshihiro Tani,

• Zhu, Wan-Jun, Tohoku University, Tohoku University Hospital, Sendai City, Japan

Wan-Jun Zhu,

• Yokoyama, Keitaro, Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan

Keitaro Yokoyama,

• Fukagawa, Masafumi, Tokai University School of Medicine, Isehara, KANAGAWA, Japan

Masafumi Fukagawa,

• Akiba, Takashi, Sekikawa Hospital, Tokyo, Japan

Takashi Akiba,

• Wolf, Myles S., Duke University , Durham, North Carolina, United States

Myles S. Wolf,

• Hirakata, Hideki N., Fukuoka Renal Clinic, Fukuoka City, Japan

Hideki N. Hirakata,

Background

Orally dosed ferric citrate hydrate (FC) corrects renal anemia in patients on hemodialysis (HD), suggesting a need for exploration of the biological differences in effects of iron supplementation using different routes of administration. To address this issue, the present study compared oral FC with intravenous saccharated ferric oxide (FO) in stable HD patients.

Methods

Six patients received 3 consecutive protocols in the first HD session of the week in a fasting state: nothing given, as control (C); oral load of FC (480 mg iron), and 5 minutes of intravenous FO (40 mg iron). Iron dynamics and biological impact on redox-inflammation status during the study (6 hours) were examined.

Results

Significant increases in serum iron and transferrin saturation (TSAT) were seen with both FC and FO. Regarding total iron-binding capacity, no changes were found in FC, whereas significant increases were seen in FO, despite the lower serum iron levels in FO, suggesting appearance of nontransferrin-binding iron (NTBI). This is suggested by the significant changes of NTBI/serum Iron ratio (%) in FO, but not in FC (Fig). Compared to C, increases were seen in serum myeloperoxidase (oxidative marker) with accompanying significant decreases in thioredoxin (anti-oxidant) in FO, whereas no changes were found in FC. While ratio of intact- to c-terminal FGF23 at 4 hours after starting HD were significantly higher with FO, as compared with C or FC.

Conclusion

Oral FC differs from intravenous FO in areas such as transferrin-binding capacity, NTBI generation, induction of oxidative stress, and FGF23 metabolism. Oral FC may have benefits in terms of iron supplementation for anemia associated with chronic kidney disease.

Funding

• Commercial Support – Japan Tobacco